Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Breast Cancer
NCT04872985Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2021
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2021; status: active, not recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04872985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872985.